Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)
Open Access
- 1 November 2020
- journal article
- research article
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 14 (6) , 807-817
Abstract
No abstract availableKeywords
Funding Information
- Johnson & Johnson Innovative Medicine
- Aegerion Pharmaceuticals
- Boehringer Ingelheim
- North Carolina GlaxoSmithKline Foundation
- Galderma
- Amgen
- Teva Pharmaceutical Industries
- Servier
- Bristol-Myers Squibb
- Alnylam Pharmaceuticals
- Amarin Corporation
- Gilead Sciences
- Bayer Fund
- AstraZeneca
- Astellas Pharma Global Development
- Merck
- Merck Sharp and Dohme United Kingdom
- Novartis
- Massachusetts Medical Society
- Sanofi
- AbbVie
- Pfizer
- Unilever
- Eli Lilly and Company
This publication has 19 references indexed in Scilit:
- Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective ManagementFrontiers in Pharmacology, 2018
- ANGPTL3 Inhibition in Homozygous Familial HypercholesterolemiaNew England Journal of Medicine, 2017
- Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterolEuropean Heart Journal, 2017
- Managing the challenging homozygous familial hypercholesterolemia patient: Academic insights and practical approaches for a severe dyslipidemia, a National Lipid Association Masters SummitJournal of Clinical Lipidology, 2017
- LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and designJournal of Clinical Lipidology, 2016
- Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis SocietyEuropean Heart Journal, 2014
- Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcomeEuropean Heart Journal, 2014
- Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis SocietyEuropean Heart Journal, 2013
- Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 studyThe Lancet, 2013
- Mechanisms of Disease: genetic causes of familial hypercholesterolemiaNature Clinical Practice Cardiovascular Medicine, 2007